A61K 47/6815
Enzymes
Official title: {Enzymes}
A61K47/6815 (Enzymes) appears on 181 US grants and 259 published applications in this corpus.
Search patents in A61K- Granted patents
- 181
- Published applications
- 259
- Assignees
- 141
- Inventors
- 512
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1979 | 1 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 3 | 0 |
| 1993 | 3 | 0 |
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 3 | 0 |
| 1997 | 5 | 0 |
| 1998 | 9 | 0 |
| 1999 | 3 | 0 |
| 2000 | 2 | 0 |
| 2001 | 5 | 1 |
| 2002 | 6 | 7 |
| 2003 | 2 | 7 |
| 2004 | 2 | 2 |
| 2005 | 5 | 7 |
| 2006 | 3 | 6 |
| 2007 | 5 | 6 |
| 2008 | 4 | 6 |
| 2009 | 1 | 5 |
| 2010 | 2 | 3 |
| 2011 | 1 | 5 |
| 2012 | 2 | 4 |
| 2013 | 8 | 12 |
| 2014 | 8 | 16 |
| 2015 | 6 | 10 |
| 2016 | 10 | 17 |
| 2017 | 9 | 10 |
| 2018 | 8 | 15 |
| 2019 | 9 | 14 |
| 2020 | 7 | 15 |
| 2021 | 8 | 13 |
| 2022 | 10 | 11 |
| 2023 | 6 | 17 |
| 2024 | 10 | 22 |
| 2025 | 8 | 15 |
| 2026 | 4 | 13 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Disruption of CD28-sialoside ligand complexes to enhance T cell activation6 Oct 2026US 12,752,014 B2The Scripps Research Institute
- Recombinant human sialidases, sialidase fusion proteins, and methods of using the same21 Jul 2026US 12,686,858 B2Palleon Pharmaceuticals Inc.
- Soluble ACE2 protein, fusion proteins thereof with an FC domain, and methods of treatment of an ACE2-related disease21 Jul 2026US 12,686,860 B2Huahui Health Ltd.
- Antibody-based method to identify, purify, and manipulate cell types and processes30 Jun 2026US 12,668,644 B2Albert Einstein College of Medicine
- Compositions and methods of use thereof for treatment of metabolic diseases and related disorders30 Dec 2025US 12,508,306 B2Washington University
- Anti-tslp nanobodies and their applications17 Sep 2026US 2026/0274941 A1Shanghai Novamab Biopharmaceuticals Co., Ltd.
- Treatment of sjogren's disease with nuclease fusion proteins3 Sep 2026US 2026/0258159 A1Resolve Therapeutics, LLC
- Antibody-conjugates for targeting of tumours expressing ptk727 Aug 2026US 2026/0248939 A1Synaffix B.V.
- Anti-transferrin receptor antibodies and uses thereof20 Aug 2026US 2026/0242498 A1Biogen MA Inc.
- Multiple formats of molecular complexes13 Aug 2026US 2026/0232831 A1FrontAim Biomedicines, Inc.
Most cited
By later US patents
- Antibody compositions for selectively inhibiting VEGF356US 6,342,219 B12002
- Antibody conjugate compositions for selectively inhibiting VEGF181US 6,342,221 B12002
- Antibody methods for selectively inhibiting VEGF117US 6,524,583 B1Board of Regents, The University of Texas System · 2003
- Method for stabilizing proteins with saccharide linked protein polymer conjugates109US 5,736,625 ACargill, Incorporated · 1998
- Stabilized polyacrylic saccharide protein conjugates105US 5,492,821 ACargill, Incorporated · 1996